Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2003

View Archived Issues

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Immune Response

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: AVI BioPharma

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Chrysalis BioTechnology

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Cubist Pharmaceuticals

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: CytRx

Adenoviral gene therapy improves myocardial perfusion in stable angina

Britannia and US WorldMeds sign licensing agreement for lofexidine

Enrollment completed in phase IIa trial of DB-289

Second of three dose levels of Oxycyte completed in phase I study

Merck presents three series of IGF-1R and IRR inhibitors

GSK scientists identify novel Lp-PLA2 inhibitors for use in atherosclerosis therapy

New HCV NS3-NS4A protease inhibitors under study at Vertex

New IKK-2 kinase inhibitors and their use covered by GSK patent

ImmunoGen scientists design new prodrugs of CC-1065 analogues

Sankyo patent describes novel IL-4 and/or IL-10 production promoters

Boehringer Ingelheim researchers present new cathepsin inhibitors

Novel antihistaminic agents prepared and tested at Sun Pharmaceutical

Merck KGaA scientists describe modulators of 5-HT activity and their use

BioBalance commences enrollment in IBS trial of Probactrix

Cengent demonstrates efficacy of anthrax lethal factor inhibitor in animals

Medivir and Roche restructure HIV alliance, enter research agreement for HCV

Dosing complete in phase I study of MM-093

Twelve-month data favor transition to bivalirudin as standard treatment

Arixtra receives European approval for extended prophylaxis of VTE

Positive results announced for aliskiren in hypertension

Potential new antidepressant, BMS-296859, with dual mechanism of action

Strong antitumor effects demonstrated for humanized anti-TF monoclonal antibody

Candidate NR2B antagonist for chronic/neuropathic pain states

Small-molecule HDAC inhibitor JNJ-16241199, a potent, orally active antitumor agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...